Intravenous Immunoglobulin Market Market Dynamics Influenced by Plasma Collection and Supply Trends

 

The global intravenous immunoglobulin (IVIG) market is experiencing substantial growth, driven by the increasing prevalence of immunodeficiency and autoimmune disorders, along with the expanding therapeutic applications of IVIG. The market is expected to be valued at US$ 15.2 billion in 2026 and is projected to reach US$ 25.9 billion by 2033, growing at a compound annual growth rate (CAGR) of 7.9% between 2026 and 2033.

Market Overview

Intravenous immunoglobulin (IVIG) is a blood product derived from human plasma, used for the treatment of a variety of immunodeficiency disorders, autoimmune diseases, and other conditions. Its applications span across chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome, myasthenia gravis, and primary immunodeficiency disorders (PID). The IVIG market is not only expanding due to rising diagnostic rates but also benefiting from increased awareness among healthcare providers and advancements in plasma fractionation technologies that improve product safety and availability.

Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/2830 

As the use of IVIG broadens, especially in neuromuscular, autoimmune, and hematological diseases, the market is expected to experience continued growth. The integration of IVIG into standard care protocols for life-threatening immune dysfunctions, particularly in emerging markets, is further fueling market demand.

Key Industry Highlights

• Leading Region: North America remains the dominant market for IVIG, driven by its advanced healthcare infrastructure, a high prevalence of immunodeficiency and autoimmune disorders, and the widespread adoption of IVIG therapy.

• Fastest-Growing Region: The Asia Pacific region is emerging as the fastest-growing market for IVIG, spurred by an increase in rare immunological diseases, improved healthcare access, and growing plasma collection infrastructure, particularly in countries like China, India, and Southeast Asia.

• Dominant Segment: Immunodeficiency disorders, particularly primary and secondary immunodeficiencies, continue to represent the largest application segment for IVIG, benefiting from lifelong treatment needs and high adoption rates.

• Fastest-Growing Segment: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is expected to be the fastest-growing segment due to better diagnostic capabilities, increasing awareness, and improved clinical guidelines for treatment.

Market Dynamics

Drivers of Market Growth

Several key factors are driving the growth of the IVIG market. A major driver is the rising global prevalence of immunodeficiency and chronic inflammatory diseases, including CIDP, Guillain-Barré syndrome, and myasthenia gravis. These diseases require long-term immunomodulatory therapy, often in the form of IVIG. As the number of diagnosed cases increases and awareness grows, the demand for IVIG therapies is expanding significantly.

Additionally, autoimmune diseases are becoming more common worldwide. According to the National Institutes of Health (NIH), autoimmune disorders affect between 5% and 8% of the U.S. population, with numbers expected to grow in the coming years. IVIG is increasingly being used as a first-line therapy for many of these conditions, further expanding the market.

Restraints on Market Growth

While the IVIG market is growing rapidly, it faces several challenges. One of the main barriers is the high cost of IVIG therapy. The cost of immunoglobulin treatments can exceed US$30,000 annually, and the ongoing nature of these treatments for chronic conditions means that many patients face substantial financial burdens. The cost per gram of IVIG can be as high as USD 73.89, further limiting its accessibility for certain populations.

Another challenge is the lack of awareness, particularly in emerging markets where patients may not be well-versed in the benefits of immunoglobulin therapy or may not seek proper medical care until later stages of illness.

Opportunities in the IVIG Market

The most significant opportunity for growth in the IVIG market lies in neuromuscular disorders such as CIDP and Multifocal Motor Neuropathy (MMN). These disorders are increasingly diagnosed, and IVIG is considered an effective treatment for them. The growing aging population and improved diagnostics are expected to further increase the number of patients requiring IVIG therapy for neuromuscular conditions.

Companies that can optimize dosing regimens, develop subcutaneous formulations for at-home use, and expand clinical indications in these high-value segments are likely to see significant market success. Additionally, as more people are diagnosed with CIDP, the frequency and volume of IVIG treatments per patient will increase.

Category-wise Analysis

Antibody Type Analysis

The majority of IVIG therapies are based on Immunoglobulin G (IgG), which is expected to continue being the leading antibody type in the market. IgG is the most widely used immunoglobulin because of its broad-spectrum immunomodulatory effects and its essential role in treating immunodeficiencies, autoimmune conditions, and neurological disorders. As clinical guidelines have long supported IgG’s use, it remains the dominant type in IVIG formulations.

While other immunoglobulins such as IgA, IgM, IgE, and IgD are present in smaller quantities, they are not typically formulated for intravenous use, resulting in a minimal market share for these isotypes.

Distribution Channel Analysis

Hospital pharmacies are expected to dominate the distribution of IVIG products, capturing around 60% of the market share by 2026. This is because most IVIG infusions are administered in hospital settings, where close monitoring is required due to the potential for infusion reactions and the complex nature of the treatment. Hospital pharmacies are responsible for managing procurement, cold-chain logistics, and product allocation, particularly during shortages.

Although retail pharmacies and specialty infusion centers are becoming more relevant in some high-income countries, hospital pharmacies remain the primary distribution channel in most global markets.

Read More: https://www.persistencemarketresearch.com/market-research/intravenous-immunoglobulin-market.asp 

Regional Insights

North America

North America is projected to maintain its dominant position in the IVIG market, accounting for 43% of the market share by 2026. The region benefits from a high awareness of immunodeficiency and autoimmune diseases, a well-established healthcare infrastructure, and robust research and development capabilities. Additionally, the increasing prevalence of autoimmune diseases in the U.S. is expected to contribute to continued growth in the IVIG market.

Asia Pacific

The Asia Pacific region is anticipated to exhibit the highest growth rate over the forecast period. Rising healthcare access, increasing awareness of immunodeficiency disorders, and expanding plasma collection infrastructure in countries like China, India, and Southeast Asia are driving the growth of the IVIG market. Furthermore, the region's aging population is contributing to the increased prevalence of immune-related diseases, which is expected to support the demand for IVIG therapies.

Competitive Landscape

The IVIG market is moderately consolidated, with a few large plasma-derived product manufacturers holding significant market share. These companies focus on securing plasma access, investing in high-yield fractionation technologies, and developing flexible infusion options, such as subcutaneous formulations and higher-concentration products.

Notable companies in the IVIG market include:

• Biotest AG

• Baxter International Inc.

• Octapharma AG

• LFB Biotechnologies

• Grifols SA

• CSL Behring

• China Biologics Products Inc.

• Kedrion Biopharma

• BDI Pharma Inc.

• Pfizer Inc.

Recent Industry Developments

In April 2022, Grifols S.A. completed its acquisition of Biotest, a strategic move that significantly strengthens its position in the IVIG market. The acquisition allows Grifols to expand its plasma-derived product range, increase patient access to plasma medicines, and enhance revenue growth. This deal also enhances Grifols’ ability to meet global demand for immunoglobulin therapies.

Conclusion

The intravenous immunoglobulin market is on an upward trajectory, fueled by a combination of rising diagnostic rates, growing awareness, and increasing therapeutic indications. While challenges such as cost and awareness remain, opportunities in neuromuscular disorders, coupled with innovations in treatment administration, are expected to further drive growth. As access to IVIG therapies improves, particularly in emerging markets, the market is poised for continued expansion in the coming years.